Markman M - Search Results

1

Markman M. Markman M. Eur J Cancer. 2005 Mar;41(5):673-5. doi: 10.1016/j.ejca.2004.12.008. Epub 2005 Jan 18. Eur J Cancer. 2005. PMID: 15763641 Review.

2

Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications.

Markman M, Webster K, Kulp B, Peterson G. Markman M, et al. Cancer Invest. 2005;23(1):33-5. Cancer Invest. 2005. PMID: 15779866

3

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.

Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Coleman RL, et al. Among authors: markman m. Eur J Cancer. 2014 Jun;50(9):1638-48. doi: 10.1016/j.ejca.2014.03.005. Epub 2014 Apr 4. Eur J Cancer. 2014. PMID: 24709487 Free PMC article. Clinical Trial.

4

Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution.

Markman M. Markman M. Cancer. 2007 Oct 15;110(8):1644-7. doi: 10.1002/cncr.22967. Cancer. 2007. PMID: 17879372 Free article. No abstract available.

5

Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.

Markman M. Markman M. Cancer. 2010 Nov 15;116(22):5116-8. doi: 10.1002/cncr.25543. Cancer. 2010. PMID: 20665504 Free article. No abstract available.

6

Influence of tumor type, disease status, and patient age on self-reported interest regarding participation in cancer clinical trials.

Markman M, Petersen J, Montgomery R. Markman M, et al. Cancer. 2006 Aug 15;107(4):849-53. doi: 10.1002/cncr.21997. Cancer. 2006. PMID: 16832813 Free article.

7

The dangers of "cross-trial" and "cross-retrospective experience" comparisons: examples employing data in the peer-reviewed ovarian cancer literature.

Markman M. Markman M. Cancer. 2007 May 15;109(10):1929-32. doi: 10.1002/cncr.22645. Cancer. 2007. PMID: 17385206 Free article. No abstract available.

8

Pharmaceutical management of ovarian cancer : current status.

Markman M. Markman M. Drugs. 2008;68(6):771-89. doi: 10.2165/00003495-200868060-00004. Drugs. 2008. PMID: 18416585 Review.

9

Hormonal therapy for epithelial ovarian cancer.

Markman M. Markman M. Womens Health (Lond). 2006 Nov;2(6):847-51. doi: 10.2217/17455057.2.6.847. Womens Health (Lond). 2006. PMID: 19804004 Free article.

10

Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity.

Markman M. Markman M. Oncologist. 2005 Oct;10(9):695-7. doi: 10.1634/theoncologist.10-9-695. Oncologist. 2005. PMID: 16249348 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

814 results

Search Page